“The biggest risk that our patients face is a severe COVID-19 episode,” says Kutikov.
Alexander Kutikov, MD, discusses his experience with the COVID-19 vaccine and patients with genitourinary cancer. Kutikov is chief, Division of Urology and Urologic Oncology, professor, Department of Surgical Oncology, and Roberta R. Scheller Chair in Urologic Oncology at Fox Chase Cancer Center.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.